Fabrication and Evaluation of Dual Peptides-Modified Liposomes Coencapsulating siRNA and Docetaxel

  • Zhenzhen YangEmail author
  • Bai Xiang
Living reference work entry

Latest version View entry history

Part of the Biomaterial Engineering book series (BIOENG)


Combination of several approaches which facilitates the blockade of multiple disease pathways has been proven highly effective in treatment of cancer cells and their microenvironment. Combinational gene therapy and chemotherapy via cationic liposomes holds great potential since it targets therapeutic agents synergistically increasing their selective accumulation at the tumor site and enhancing their efficacy allowing administration of lower doses of each agent, thus reducing their side effects. The present protocol describes the fabrication methods to obtain the reliable stealth liposomes coencapsulating vascular endothelial growth factor (VEGF) targeting small interfering RNA (siRNA), which can inhibit angiogenesis, and chemotherapeutic docetaxel (DTX), which can kill tumor cells efficiently. Besides, two receptor-specific peptides, specifically low-density lipoprotein receptor-related protein receptor (Angiopep-2) and neuropilin-1 receptor (tLyP-1), were attached on the stealth liposomes for tumor targeting and penetration.


Dual peptides-modified liposomes Coencapsulate siRNA Docetaxel VEGF 


  1. Aagaard L, Rossi JJ (2007) RNAi therapeutics: principles, prospects and challenges. Adv Drug Deliv Rev 59:75–86CrossRefGoogle Scholar
  2. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257CrossRefGoogle Scholar
  3. Chen AM, Zhang M, Wei D, Stueber D, Taratula O, Minko T et al (2009) Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small 5(23):2673–2677CrossRefGoogle Scholar
  4. Chen Y, Wu JJ, Huang L (2010) Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy. Mol Ther 18(4):828–834CrossRefGoogle Scholar
  5. Creixell M, Peppas NA (2012) Co-delivery of siRNA and therapeutic agents using nanocarriers to overcome cancer resistance. Nano Today 7:367–379CrossRefGoogle Scholar
  6. Demeule M, Currie JC, Bertrand Y, Che C, Nguyen T, Regina A, Gabathuler R, Castaigne JP, Beliveau R (2008) Involvement of the low-density lipoprotein receptor-related protein in the transcytosis of the brain delivery vector angiopep-2. J Neurochem 106:1534–1544CrossRefGoogle Scholar
  7. Dong DW, Xiang B, Gao W, Yang ZZ, Li JQ, Qi XR (2013) pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells. Biomaterials 34:4849–4859CrossRefGoogle Scholar
  8. Eldar-Boock A, Polyak D, Scomparin A, Satchi-Fainaro R (2013) Nano-sized polymers and liposomes designed to deliver combination therapy for cancer. Curr Opin Biotechnol 24:682–689CrossRefGoogle Scholar
  9. Frumovitz M, Sood AK (2007) Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol 104:768–778CrossRefGoogle Scholar
  10. Gavrilov K, Saltzman WM (2012) Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med 85(2):187–200Google Scholar
  11. Hardee ME, Zagzag D (2012) Mechanisms of glioma-associated neovascularization. Am J Pathol 181(4):1126–1141CrossRefGoogle Scholar
  12. Hussain MM, Strickland DK, Bakillah A (1999) The mammalian low-density lipoprotein receptor family. Annu Rev Nutr 19:141–172CrossRefGoogle Scholar
  13. Miller CR, Bondurant B, Mclean SD, Mcgovern KA, Obrien DF (1998) Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. Biochemistry 37:12875–12883CrossRefGoogle Scholar
  14. Oh YK, Park TG (2009) siRNA delivery systems for cancer treatment. Adv Drug Deliv Rev 61:850–862CrossRefGoogle Scholar
  15. Ozcan G, Ozpolat B, Coleman RL, Sood AK, Lopezberestein G (2015) Priclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev 87:108–119CrossRefGoogle Scholar
  16. Roth L, Agemy L, Kotamraju VR, Braun G, Teesalu T, Sugahara KN, Hamzah J, Ruoslahti E (2011) Transtumoral targeting enabled by a novel neuropilin-binding peptide. Oncogene 31:3754–3763CrossRefGoogle Scholar
  17. Saad M, Garbuzenko OB, Minko T (2008) Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer. Nanomedicine (London) 3(6):761–776CrossRefGoogle Scholar
  18. Upadhyay KK, Bhatt AN, Castro E, Mishra AK, Chuttani K, Dwarakanath B, Schatz C, Le Meins JF, Misra A, Lecommandoux S (2010) In vitro and in vivo evaluation of docetaxel loaded biodegradable polymersomes. Macromol Biosci 10:503–512CrossRefGoogle Scholar
  19. Xin HL, Jiang XY, JJ G, Sha XY, Chen LC, Law KK, JJ G, Chen YZ, Wang X, Fang XL (2011) Angiopep-conjugated poly(ethylene glycol)-co-poly(epsilon-caprolactone) nanoparticles as dual Targeting drug delivery system for brain glioma. Biomaterials 32:4293–4305CrossRefGoogle Scholar
  20. Xiong XB, Lavasanifar A (2011) Traceable multifunctional micellar nanocarriers for cancer-targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 5:5202–5213CrossRefGoogle Scholar
  21. Yang ZZ, Li JQ, Wang ZZ, Dong DW, Qi XR (2014a) Tumor-targeting dual peptides-modified cationic liposomes for delivery of siRNA and docetaxel to gliomas. Biomaterials 35:5226–5239CrossRefGoogle Scholar
  22. Yang ZZ, Xiang B, Dong DW, Wang ZZ, Li JQ, Qi XR (2014b) Dual receptor-specific peptides modified liposomes as VEGF siRNA vector for tumor-targeting therapy. Curr Gene Ther 14(4):289–299CrossRefGoogle Scholar
  23. Yang ZZ, Gao W, Liu YJ, Pang N, Qi XR (2017) Delivering siRNA and chemotherapeutic molecules across BBB and BTB for intracranial glioblastoma therapy. Mol Pharm 14(4):1012–1022CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Beijing Key Laboratory of Molecular Pharmaceutics and New drug delivery System, Department of pharmaceutics, School of Pharmaceutical Sciences, Peking UniversityBeijingPeople’s Republic of China
  2. 2.Department of Pharmaceutics, School of Pharmaceutical SciencesHebei Medical UniversityShijiazhuangPeople’s Republic of China

Personalised recommendations